Skip to main content
Premium Trial:

Request an Annual Quote

Bionomics Shareholders OK Iliad Acquisition, Green-Light $4.6M Stock Placement

NEW YORK, June 27 (GenomeWeb News) - Australian biotech Bionomics shareholders today approved the company's acquisition of Iliad Chemicals, the company said today. The shareholders also gave the company the green light to raise AU$6 million ($4.6 million).

 

Bionomics said last month that it planned to acquire the privately held drug-discovery company Iliad Chemicals for AU$9 million. At the time, the company said it had completed an AU$6 million placement, subject to today's shareholder approval, to fund development programs in cancer and central nervous system disorders.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.